$8.43 -0.15 (-1.75%)
11/27/2009 1:00 PM

Albany Molecular Research, Inc. (AMRI)

CAPS Rating: 3 out of 5

The Company is a global chemistry-based drug discovery and development company focused on identifying and developing novel biologically active small molecules with applications in the drug market.

Results 1 - 13 of 13

Recs

0
Member Avatar brianpivar (97.70) Submitted: 11/4/2009 8:15:24 PM : Underperform Start Price: $8.16 AMRI Score: +0.39

EPS 08: .62 p/e 13.1
EPS 09: .05 p/e 162.8
EPS 10: .13 p/e 62.62

Fundamentally speaking, this is a sell

Recs

0
Member Avatar dusand (95.08) Submitted: 9/18/2009 10:25:21 AM : Outperform Start Price: $8.29 AMRI Score: -0.57

Profitable pharmacy research and development company with good valuation ratios and low debt. Also, I feel the chart has already reached the bottom.

Recs

0
Member Avatar NWTOGME (< 20) Submitted: 10/4/2008 3:19:52 PM : Outperform Start Price: $14.21 AMRI Score: -45.59

L/R D/E ratio's look good.

Recs

0
Member Avatar equalfuture (38.62) Submitted: 4/10/2008 4:52:05 AM : Outperform Start Price: $11.74 AMRI Score: -12.12

BUYING AT 5 PER SHARE, stock is valued in my fair value estimates at 5.40 a share i expect movement at this price in late summer.

good company worth 5 or more a share.

Recs

0
Member Avatar samlove (< 20) Submitted: 1/2/2008 1:52:56 PM : Outperform Start Price: $13.70 AMRI Score: -17.40

On a strictly technical basis, my magic charts say this will outperform the S&P

Recs

0
Member Avatar unclestalin (43.94) Submitted: 11/8/2007 11:17:03 AM : Outperform Start Price: $11.67 AMRI Score: -5.59

total risky pick here. But I live close to albany molecular, and they are a big deal in town. granted it's albany ny though. I have seen them working on stuff, their head honchos are decent people and their workers are all high quality.

Recs

0
Member Avatar NeroSagetrade (87.82) Submitted: 10/9/2007 11:05:33 PM : Outperform Start Price: $16.83 AMRI Score: -23.48

Albany Molecular Research is another case of the slow and steady turtle executing with a solid management team to deliver results. The past four quarters have shown rather large earnings beats and at 31 times earnings and with $3.14 per share in cash I think they can solidly deliver 15% stock price appreciation per annum. The price to book valuation is in-line if not just below the sector average and the long-term technicals show an ascending triangle that wants to break hgiher above $18. All signs pointing higher.

Nero

Sagetrade

Recs

0
Member Avatar xylitol02 (< 20) Submitted: 7/19/2007 5:37:06 AM : Outperform Start Price: $16.81 AMRI Score: -24.17

new

Recs

0
Member Avatar Brob84 (< 20) Submitted: 6/23/2007 1:22:57 PM : Outperform Start Price: $14.70 AMRI Score: -19.43

Growing by pharmaceutical development and licensing or partnership with large pharma corps.

Recs

0
Member Avatar traderz999 (< 20) Submitted: 6/17/2007 6:21:27 PM : Outperform Start Price: $15.06 AMRI Score: -19.22

sc score 10, good earning forecast

Recs

0
Member Avatar GaTeek (< 20) Submitted: 5/3/2007 6:57:10 PM : Outperform Start Price: $10.65 AMRI Score: +2.31

Lagging CRO sector, plus participation in near term drug discovery candidates

Recs

0
Member Avatar skc0001 (< 20) Submitted: 10/30/2006 3:11:34 AM : Outperform Start Price: $11.91 AMRI Score: -13.73

a VALUE PROPOSITION

Recs

0
Member Avatar edrc (87.09) Submitted: 10/24/2006 2:58:31 PM : Outperform Start Price: $11.38 AMRI Score: -10.74

Strong company, recent run up on no news suggest good news coming.

Results 1 - 13 of 13

Featured Broker Partners